Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin in MRSA Skin Infections, Septicemia, and Endocarditis
NCT00770341Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Feb 2010
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
A Phase 3 trial of daptomycin in skin and soft tissue infection (SSTI), sepsis, infective endocarditis (IE), sponsored by Merck & Co.. Started Sep 2008; status: completed.
02
Drugs
daptomycin
03
Conditions
skin and soft tissue infection (SSTI)sepsisinfective endocarditis (IE)
Beyond the preview
Go deeper on NCT00770341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770341.